Fibroblast growth factor 23: Associations with cardiovascular disease and mortality in chronic kidney disease

International Urology and Nephrology

Volumn 46, Issue 1, 2014, Pages 9-17

  Negri, Armando Luis ^a  

^a UNIVERSIDAD DEL SALVADOR   (Argentina)

Author keywords

Cardiovascular disease; Cardiovascular mortality; Chronic kidney disease; FGF 23; Ventricular hypertrophy

Indexed keywords

CARDIOVASCULAR DISEASES; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; KIDNEY FAILURE, CHRONIC; PHOSPHATES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D;

EID: 84893838264     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0370-2     Document Type: Review

References (61)

1. Quarles LD (2012) Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res 318(9):1040-1048
2. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429-435 (Pubitemid 38787398)
3. Bai X, Miao D, Li J et al (2004) Transgenic mice overexpressing human fibroblast growth factor 23(R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145:5269-5279 (Pubitemid 39551149)
4. Larsson T, Marsell R, Schipani E et al (2004) Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha 1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087-3094 (Pubitemid 38829975)
5. Shimada T, Urakawa I, Yamazaki Y et al (2004) FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314:409-414 (Pubitemid 38084732)
6. Razzaque MS, St-Arnaud R, Taguchi T et al (2005) FGF-23, vitamin D and calcification: the unholy triad. Nephrol Dial Transplant 20:2032-2035 (Pubitemid 41510074)
7. Memon F, El-Abbadi M, Nakatani T et al (2008) Does Fgf23-klotho activity influence vascular and soft tissue calcification through regulating mineral ion metabolism? Kidney Int 74:566-570
8. DeLuca S, Sitara D, Kang K et al (2008) Amelioration of the premature aging-like features of Fgf-23 knockout mice by genetically restoring the systemic actions of FGF-23. J Pathol 216:345-355
9. ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR consortium. Nat Genet 26:345-348
10. Benet-Pagès A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM (2004) FGF23 is processed by proprotein convertases but not by PHEX. Bone 35(2):455-462 (Pubitemid 38953193)
11. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. PNAS 98:6500-6505 (Pubitemid 32488266)
12. Goetz R, Beenken A, Ibrahimi OA et al (2007) Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27:3417-3428 (Pubitemid 46685217)
13. Razzaque MS, Lanske B (2006) Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med 12:298-305 (Pubitemid 44110001)
14. Razzaque MS, Sitara D, Taguchi T et al (2006) Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. Faseb J 20:720-722 (Pubitemid 46671193)
15. Urakawa I, Yamazaki Y, Shimada T et al (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774 (Pubitemid 44949607)
16. Levin A, Bakris GL, Molitch M et al (2007) Prevalence of abnormal serum vitamin D, PTH, calcium and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 712:31-38 (Pubitemid 44967731)
17. Gutierrez O, Isakova T, Rhee E et al (2005) Fibroblast growth factor- 23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205-22015 (Pubitemid 41716454)
18. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T (2010) Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78(10):975-980
19. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG (2012) FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. Clin Invest 122(7):2543-2553
20. Krajisnik T, Olauson H, Mirza MA, Hellman P, Akerström G, Westin G, Larsson TE, Björklund P (2010) Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 78(10):1024-1032
21. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T (2010) Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 77:211-218
22. Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, Mendoza FJ, Munoz-Castaneda JR, Shalhoub V, Almaden Y, Rodriguez M (2010) FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 21(7):1125-1135
23. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299(4):F882-F889
24. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359(6):584-592
25. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24(9):2792-2796
26. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I (2011) Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 22(5):956-966
27. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G (2011) HOST Investigators. FGF-23 Associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22(10):1913-1922
28. Kanbay M, Nicoleta M, Selcoki Y et al (2010) Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol 5:1780-1786
29. Kanbay M, Wolf M, Selcoki Y, Solak Y, Ikizek M, Uysal S, Segall L, Armutcu F, Eryonucu B, Duranay M, Goldsmith D, Covic A (2012) Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease. Int Urol Nephrol 44(4):1169-1175
30. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH (2010) FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 25:3983-3989
31. Isakova T, Xie H, Yang W et al (2011) Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305:2432-2439
32. Parker BD, Schurgers LJ, Brandenburg VM et al (2010) The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 152:640-648
33. Mirza MA, Larsson A, Lind L, Larsson TE (2009) Circulating fibroblast growth factor- 23 is associated with vascular dysfunction in the community. Atherosclerosis 205:385-390
34. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, Siscovick DS, Sarnak MJ, Shlipak MG (2012) Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol (JACC) 60(3):200-207
35. Arnlöv J, Carlsson AC, Sundström J, Ingelsson E, Larsson A, Lind L, Larsson TE (2012) Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int (Epub ahead of print)
36. Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G (2012) An update on uremic toxins. Int Urol Nephrol. (Epub ahead of print) PubMed PMID: 22893494
37. Donate-Correa J, Mora-Fernández C, Martínez-Sanz R, Muros-de-Fuentes M, Pérez H, Meneses-Pérez B, Cazaña- Pérez V, Navarro-González JF (2011) Expression of FGF23/KLOTHO system in human vascular tissue. Int J Cardiol (Epub ahead of print)
38. Ikushima M, Rakugi H, Ishikawa K et al (2006) Anti-apoptotic and anti-senescence effects of Klotho on vascular endothelial cells. Biochem Biophys Res Commun 339:827-832 (Pubitemid 41772888)
39. Liu P, Bai X, Wang H, Karaplis A, Goltzman D, Miao D (2009) Hypophosphatemia mediated hypotension in transgenic mice overexpressing human FGF-23. Am J Physiol Heart Circ Physiol 297:H1514-H1520
40. Mirza MA, Alsio J, Hammarstedt A et al (2010) Circulating fibroblast growth factor- 23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 31:219-227
41. Park W, Kim BS, Lee JE et al (2009) Serum phosphate levels and the risk of cardiovascular disease and metabolic syndrome: a double-edged sword. Diabetes Res Clin Pract 83:119-125
42. Ellam T, Wilkie M, Chamberlain J et al (2011) Dietary phosphate modulates atherogenesis and insulin resistance in apolipoprotein e knockout mice. Arterioscler Thromb Vasc Biol 31:1988-1990
43. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE (2009) Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207(2):546-551
44. Gutierrez OM et al (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119(19):2545-2552
45. Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16(2):139-149 (Pubitemid 40616112)
46. Itoh N, Ornitz DM (2011) Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 149(2):121-130
47. Detillieux KA, Sheikh F, Kardami E, Cattini PA (2003) Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 57(1):8-19 (Pubitemid 36009431)
48. Parker TG, Parker SE, Schneider MD (1990) Peptide growth factors can provoke "fetal" contractile gene expression in rat cardiac myocytes. J Clin Invest 85(2):507-514 (Pubitemid 20070059)
49. Scheinowitz M, Kotlyar A, Zimand S, Ohad D, Leibovitz I, Bloom N, Goldberg I, Nass D, Engelberg S, Savion N, Eldar M (1998) Basic fibroblast growth factor induces myocardial hypertrophy following acute infarction in rats. Exp Physiol 83(5):585-593 (Pubitemid 28458390)
50. Corda S, Mebazaa A, Gandolfini MP, Fitting C, Marotte F, Peynet J, Charlemagne D, Cavaillon JM, Payen D, Rappaport L, Samuel JL (1997) Trophic effect of human pericardial fluid on adult cardiac myocytes. Differential role of fibroblast growth factor-2 and factors related to ventricular hypertrophy. Circ Res 81(5):679-687 (Pubitemid 27467202)
51. Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7(8):589-600 (Pubitemid 44325350)
52. Molkentin JD (2004) Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 63(3):467-475 (Pubitemid 38970191)
53. Muslin AJ (2008) MAPK signaling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond) 115(7):203-218
54. Chung E, Yeung F, Leinwand LA (2012) Akt and MAPK signaling mediate pregnancy-induced cardiac adaptation. J Appl Physiol 112(9):1564-1575
55. Faul C, Amaral AP, Oskouei B et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121(11):4393-4408
56. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM (2010) Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5(2):286-291
57. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM (2012) Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23(8):1407-1415
58. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker GE (2012) Effects of sevelamer on HbA1c, inflammation, and advanced glycation End products in diabetic kidney disease. Clin J Am Soc Nephrol 7(6):934-942
59. Isakova T, Gutiérrez OM, Smith K, Epstein M, Keating LK, Jüppner H, Wolf M (2011) Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 26(2):584-591
60. Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL, Donahue SE, Asplin JR (2011) Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 6(2):257-264
61. Hryszko T, Brzosko S, Rydzewska-Rosolowska A, Koc-Zorawska E, Mysliwiec M (2012) Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism. Int Urol Nephrol 44(5):1479-1486